A Phase I, Multi-center, Open-label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR104 Given Weekly in Subjects With Solid Tumors.
Latest Information Update: 24 May 2011
At a glance
- Drugs PR 104 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 24 May 2011 New trial record